OncoMatch/Clinical Trials/NCT06852365
Combined Oral Contraceptive Pill and Resistance Starch
Is NCT06852365 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Oral Contraceptives, Low-Dose for metabolic syndrome.
Treatment: Oral Contraceptives, Low-Dose — This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
hemoglobin >= 10 mg/dl
Kidney function
bun <= 30 mg/dl, serum creatinine <= 1.4 mg/dl
Liver function
ast/alt <= 2x normal, total bilirubin <= 2.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06852365 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 40 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify